Leiden: For people whose lungs are slowly turning to scar tissue, the menu of treatments has been short and the prognosis bleak. That may be about to change. The European Medicines Agency’s human-medicines committee has recommended approval for a clutch of new therapies, and among them is one aimed squarely at pulmonary fibrosis, a group of conditions in which the lung’s delicate architecture stiffens until breathing becomes a daily struggle.
The drug, developed by Boehringer Ingelheim and carrying the trade name Jascayd, is built around a compound called nerandomilast. The committee backed it for idiopathic pulmonary fibrosis, where the cause is unknown, as well as for progressive pulmonary fibrosis driven by other underlying diseases. For a field that has seen few genuinely new mechanisms reach the clinic, the recommendation is notable not merely as another approval but as a potential addition to a thin therapeutic arsenal.
A positive opinion from the committee is not the final word. It is a recommendation to the European Commission, which issues the formal market authorisation valid across the Union, and the pricing and reimbursement battles that follow play out country by country. But the committee’s endorsement is the scientific gate through which every new medicine must pass, and clearing it signals that regulators judged the benefits to outweigh the risks on the evidence presented.
The pulmonary-fibrosis recommendation arrived as part of a broader slate. The committee backed several new medicines in its latest round alongside more than a dozen extensions that widen the approved uses of drugs already on the market, the unglamorous but important work of letting existing treatments reach more patients. Taken together, the batch is a reminder that the agency’s output is less about occasional breakthroughs than a steady cadence of incremental decisions that quietly reshape what doctors can prescribe.
That cadence was underlined this week by the agency’s publication of its annual report for last year, which recorded scores of recommendations for human medicines across the twelve months. The numbers describe a regulatory machine working at high volume, and they feed a longer debate about whether Europe approves innovative therapies quickly enough to keep pace with the United States, a comparison the continent’s pharmaceutical industry raises whenever the subject of competitiveness comes up.
For the clinicians who treat fibrosis, the abstractions of regulatory throughput matter less than the practical question of what they can offer a frightened patient. Existing therapies can slow the decline of lung function but do not reverse it, and many patients struggle with side effects or eventually progress regardless. A new option with a different mechanism, if it survives the journey from committee opinion to pharmacy shelf and proves affordable to national health systems, expands the room for manoeuvre. The caveats are real, the timelines uncertain, but for a disease that has long outrun medicine, an additional weapon is welcome news.
